Astrazeneca (AZN) Research & Development (2009 - 2026)
Astrazeneca (AZN) posted quarterly Research & Development of $4.1 billion for Q2 2026, up 14.23% year-over-year from $3.5 billion in Q2 2025, and up 216.07% quarter-over-quarter from -$3.5 billion in Q1 2026.
Astrazeneca (AZN) Research & Development (2009 - 2026) Analysis & Trends
Astrazeneca's Research & Development history runs 18 years deep, the most recent figure standing at $4.1 billion for Q2 2026.
- In Q2 2026, Research & Development rose 14.23% year-over-year to $4.1 billion; the TTM figure through Jun 2026 stood at -$7.0 billion (up 5.93% YoY), while the FY2025 annual figure was $14.2 billion, up 4.78% from the prior year.
- Research & Development for Q2 2026 stood at $4.1 billion, up from -$3.5 billion in the prior quarter.
- The five-year high for Research & Development was $4.1 billion in Q2 2026, with the low at -$4.7 billion in Q4 2024.
- The 5-year median for Research & Development is -$2.7 billion (2023), against an average of -$2.3 billion.
- The sharpest annual moves came in 2022 and 2025: Research & Development tumbled 606.29% in 2022, then jumped 217.95% in 2025.
- Astrazeneca's Research & Development stood at -$2.6 billion in 2022, then decreased by 17.07% to -$3.1 billion in 2023, then tumbled by 52.2% to -$4.7 billion in 2024, then advanced by 17.43% to -$3.9 billion in 2025, then surged by 204.95% to $4.1 billion in 2026.
- Business Quant data shows AZN's Research & Development at $4.1 billion in Q2 2026, -$3.5 billion in Q1 2026, and -$3.9 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -2.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.05 Bn |
| Mar 31, 2026 | -3.49 Bn |
| Dec 31, 2025 | -3.86 Bn |
| Sep 30, 2025 | -3.66 Bn |
| Jun 30, 2025 | 3.55 Bn |
| Mar 31, 2025 | -3.16 Bn |
| Dec 31, 2024 | -4.68 Bn |
| Sep 30, 2024 | -3.12 Bn |
| Jun 30, 2024 | -3.01 Bn |
| Mar 31, 2024 | -2.78 Bn |
| Dec 31, 2023 | -3.07 Bn |
| Sep 30, 2023 | -2.58 Bn |
| Jun 30, 2023 | -2.67 Bn |
| Mar 31, 2023 | -2.61 Bn |
| Dec 31, 2022 | -2.63 Bn |
| Sep 30, 2022 | -2.46 Bn |
| Jun 30, 2022 | -2.55 Bn |
| Mar 31, 2022 | -2.13 Bn |
| Dec 31, 2021 | -2.58 Bn |
| Sep 30, 2021 | -3.61 Bn |